MCID: PNC013
MIFTS: 47

Pancreatic Ductal Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Ductal Carcinoma

MalaCards integrated aliases for Pancreatic Ductal Carcinoma:

Name: Pancreatic Ductal Carcinoma 12 15
Carcinoma, Pancreatic Ductal 45 74
Malignant Neoplasm of Duct of Wirsung 12
Carcinoma Pancreatic Ductal 56
Pancreatic Duct Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3587
ICD9CM 36 157.3
MeSH 45 D021441
SNOMED-CT 69 93939009
ICD10 34 C25.3

Summaries for Pancreatic Ductal Carcinoma

Disease Ontology : 12 A pancreatic carcinoma located in the pancreatic duct.

MalaCards based summary : Pancreatic Ductal Carcinoma, also known as carcinoma, pancreatic ductal, is related to microcystic adenoma and cystadenocarcinoma. An important gene associated with Pancreatic Ductal Carcinoma is MUC6 (Mucin 6, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Gemcitabine and Axitinib have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and bone, and related phenotypes are cellular and neoplasm

Related Diseases for Pancreatic Ductal Carcinoma

Diseases related to Pancreatic Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 264)
# Related Disease Score Top Affiliating Genes
1 microcystic adenoma 30.5 MUC1 MUC6
2 cystadenocarcinoma 29.3 KRT7 MUC1 MUC2 TP53 VEGFA
3 adenocarcinoma 28.8 CDKN2A MUC1 SMAD4 TP53 VEGFA
4 pancreatic cancer 28.3 CDKN2A MUC1 MUC2 SMAD4 TP53 VEGFA
5 pancreatic adenosquamous carcinoma 11.3
6 nodular hidradenoma 10.4 KRT7 MUC1
7 parachordoma 10.4 KRT7 MUC1
8 sertoli-leydig cell tumor 10.4 KRT7 MUC1
9 mucinous ovarian cystadenoma 10.4 KRT7 MUC1
10 hidradenoma 10.4 KRT7 MUC1
11 spindle cell sarcoma 10.4 KRT7 MUC1
12 secretory meningioma 10.4 KRT7 MUC1
13 sclerosing hemangioma 10.4 KRT7 MUC1
14 middle ear adenoma 10.4 KRT7 MUC1
15 lipoadenoma 10.4 KRT7 MUC1
16 monophasic synovial sarcoma 10.4 KRT7 MUC1
17 brachydactyly, type e1 10.4 KRT20 MUC1
18 villous adenoma 10.4 KRT20 MUC1
19 pancreatic serous cystadenoma 10.4 KRT7 VEGFA
20 dendritic cell tumor 10.4 KRT20 MUC1
21 jejunal adenocarcinoma 10.4 KRT20 KRT7
22 immune system organ benign neoplasm 10.4 KRT20 KRT7
23 bladder lymphoma 10.4 KRT20 KRT7
24 chronic cystitis 10.4 KRT20 KRT7
25 thymus lipoma 10.4 KRT20 KRT7
26 rectum adenocarcinoma 10.4 KRT20 KRT7
27 prostatic acinar adenocarcinoma 10.4 KRT20 KRT7
28 bladder adenocarcinoma 10.4 KRT20 KRT7
29 infiltrative basal cell carcinoma 10.4 KRT20 KRT7
30 medulloepithelioma 10.4 KRT20 KRT7
31 thymus adenocarcinoma 10.4 KRT20 KRT7
32 ovarian cystic teratoma 10.4 KRT20 KRT7
33 adenoid squamous cell carcinoma 10.4 KRT20 KRT7
34 gastric diffuse adenocarcinoma 10.4 KRT20 KRT7
35 lung acinar adenocarcinoma 10.4 KRT20 KRT7
36 intratubular embryonal carcinoma 10.4 KRT20 KRT7
37 meibomian cyst 10.4 KRT20 KRT7
38 horseshoe kidney 10.4 KRT20 KRT7
39 small cell carcinoma of the bladder 10.4 KRT20 KRT7
40 tn polyagglutination syndrome 10.4 MUC1 MUC2
41 meconium ileus 10.4 MUC1 MUC2
42 chronic myocardial ischemia 10.4 TYMP VEGFA
43 superior mesenteric artery syndrome 10.4 MUC2 MUC6
44 papilloma of choroid plexus 10.3 MUC1 TP53
45 chordoid glioma 10.3 MUC1 TP53
46 sarcomatoid renal cell carcinoma 10.3 MUC1 TP53
47 cerebral primitive neuroectodermal tumor 10.3 MUC1 TP53
48 prostate squamous cell carcinoma 10.3 KRT7 TP53
49 mixed cell type cancer 10.3 KRT7 TP53
50 female reproductive endometrioid cancer 10.3 KRT7 TP53

Graphical network of the top 20 diseases related to Pancreatic Ductal Carcinoma:



Diseases related to Pancreatic Ductal Carcinoma

Symptoms & Phenotypes for Pancreatic Ductal Carcinoma

MGI Mouse Phenotypes related to Pancreatic Ductal Carcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.56 CDKN2A KRT7 MUC2 SMAD4 TGM2 TP53
2 neoplasm MP:0002006 9.1 CDKN2A MUC2 SMAD4 TGM2 TP53 VEGFA

Drugs & Therapeutics for Pancreatic Ductal Carcinoma

Drugs for Pancreatic Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
2
Axitinib Approved, Investigational Phase 3 319460-85-0 6450551
3
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
4
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
5 Protein Kinase Inhibitors Phase 3
6 Antiviral Agents Phase 3,Phase 1,Phase 2
7 Antimetabolites Phase 3,Phase 1,Phase 2
8 Anti-Infective Agents Phase 3,Phase 1,Phase 2
9 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
10 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
11 Immunologic Factors Phase 3,Phase 1,Phase 2,Early Phase 1
12 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2
13 Antimitotic Agents Phase 3,Phase 1,Phase 2
14 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
15 Protective Agents Phase 3,Phase 1
16 Adjuvants, Immunologic Phase 3
17 acivicin Phase 3
18 Viscosupplements Phase 3
19
Pancrelipase Approved, Investigational Phase 2,Phase 1,Not Applicable 53608-75-6
20
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
21
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
22
Durvalumab Approved, Investigational Phase 1, Phase 2,Phase 2 1428935-60-7
23
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 6857599 5310940 9887054 43805
24
Fluorouracil Approved Phase 2,Phase 1 51-21-8 3385
25
Irinotecan Approved, Investigational Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
26
leucovorin Approved Phase 2,Phase 1 58-05-9 6006 143
27
Olaparib Approved Phase 2 763113-22-0 23725625
28
Doxil Approved June 1999 Phase 2 31703
29
Tremelimumab Investigational Phase 2,Phase 1 745013-59-6
30
Apaziquone Investigational Phase 1, Phase 2 114560-48-4 5813717
31 pancreatin Phase 2,Phase 1,Not Applicable
32
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
33 Anti-Bacterial Agents Phase 2
34 Antibiotics, Antitubercular Phase 2
35 Topoisomerase Inhibitors Phase 2,Phase 1
36 Antibodies Phase 1, Phase 2,Phase 2,Early Phase 1
37 Immunoglobulins Phase 1, Phase 2,Phase 2,Early Phase 1
38 Antibodies, Monoclonal Phase 1, Phase 2,Phase 2,Early Phase 1
39 Antineoplastic Agents, Immunological Phase 1, Phase 2,Phase 2
40 Cola Phase 1, Phase 2
41 Vaccines Phase 2
42 topoisomerase I inhibitors Phase 2,Phase 1
43
s 1 (combination) Phase 2
44 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
45
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
46
Carboplatin Approved Phase 1 41575-94-4 38904 10339178 498142
47
Levoleucovorin Approved, Investigational Phase 1 68538-85-2
48
Cisplatin Approved Phase 1 15663-27-1 441203 84093 2767
49
Etoposide Approved Phase 1 33419-42-0 36462
50
Calcium Approved, Nutraceutical Phase 1 7440-70-2 271

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer. Completed NCT00471146 Phase 3 AG-013736;Gemcitabine;Gemcitabine;placebo
2 A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Active, not recruiting NCT02715804 Phase 3 Placebo;Nab-paclitaxel;Gemcitabine
3 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
4 Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer Unknown status NCT01394120 Phase 2 Targeted Therapy Tailored Treatment;Standard Chemotherapy
5 Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer Completed NCT01580397 Phase 2 INNO-206
6 Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Completed NCT02583477 Phase 1, Phase 2 MEDI4736 in combination with nab-paclitaxel and gemcitabine;MEDI4736 in combination with AZD5069
7 Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Completed NCT02558894 Phase 2 MEDI4736 monotherapy;tremelimumab+MEDI4736
8 PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer Completed NCT01839487 Phase 2 PEGPH20+nab-paclitaxel+gemcitabine;nab-paclitaxel + gemcitabine
9 QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer Completed NCT01040000 Phase 1, Phase 2 NPC-1C/NEO-102
10 Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer Completed NCT00226746 Phase 2 Paclitaxel and gemcitabine
11 Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) Completed NCT01808638 Phase 1, Phase 2 Atu027 & gemcitabine in lead in safety period;Atu027 & gemcitabine in treatment arm 1;Atu027 & gemcitabine in treatment arm 2
12 Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer Completed NCT02653313 Phase 1, Phase 2 Parvovirus H-1 (H-1PV)
13 A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer Completed NCT00902291 Phase 2
14 A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 Completed NCT01608711 Phase 2
15 Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer Recruiting NCT03848182 Phase 2 Gemcitabine
16 Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer Recruiting NCT02529579 Phase 1, Phase 2 Gemcitabine
17 The Combination Chemotherapy of SIRIOX as First‑Line Chemotherapy for Pancreatic Cancer Recruiting NCT03403101 Phase 2 S1;Oxaliplatin;Irinotecan
18 Phase II Trial of AZD6738 Alone and in Combination With Olaparib Recruiting NCT03682289 Phase 2 ATR Kinase Inhibitor AZD6738;Olaparib
19 Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Terminated NCT02243007 Phase 2 FOLFIRINOX;Gemcitabine/nab-Paclitaxel;Capecitabine
20 A Dose-Finding Study of MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) Completed NCT02259114 Phase 1 MK-8628
21 A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Completed NCT01478685 Phase 1 CC-486;Carboplatin;ABI-007
22 Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors Active, not recruiting NCT02658214 Phase 1 paclitaxel + carboplatin;carboplatin + etoposide;gemcitabine + carboplatin;nab-paclitaxel (paclitaxel-albumin) + carboplatin;oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid);nab-paclitaxel (paclitaxel-albumin) + gemcitabine;cisplatin + 5-fluorouracil (5FU)
23 A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer Active, not recruiting NCT02231723 Phase 1 BBI608;Nab-paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Irinotecan;Fluorouracil;MM-398
24 According CTC to Compare the Influences of Different Methods to Remove the PDAC Unknown status NCT02451384 Not Applicable
25 An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy Unknown status NCT02310230 Not Applicable
26 Circulating Tumor Cells in Operative Blood Completed NCT02150746
27 Clinical Trial of Pancreatic Cancer in Stockholm. Completed NCT02162823
28 Continuous Monitoring on the General Ward Completed NCT02933307 Not Applicable
29 CT Pancreas Perfusion Completed NCT00588367
30 Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma Recruiting NCT02928081 Not Applicable
31 Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection Recruiting NCT02750657
32 Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1) Recruiting NCT03513705 Not Applicable
33 Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study. Recruiting NCT03500068 Not Applicable
34 Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas Recruiting NCT02817308 Not Applicable
35 Detection of MicroRNA-25 in the Diagnosis of Pancreatic Cancer Not yet recruiting NCT03432624
36 Amatuximab for High Mesothelin Cancers Terminated NCT01413451 Early Phase 1 Amatuximab (MORab-009)
37 Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients Terminated NCT02456051

Search NIH Clinical Center for Pancreatic Ductal Carcinoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: carcinoma, pancreatic ductal

Genetic Tests for Pancreatic Ductal Carcinoma

Anatomical Context for Pancreatic Ductal Carcinoma

MalaCards organs/tissues related to Pancreatic Ductal Carcinoma:

42
Pancreas, Liver, Bone, Endothelial, Bone Marrow, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Ductal Carcinoma:

20
The Pancreatic Duct

Publications for Pancreatic Ductal Carcinoma

Articles related to Pancreatic Ductal Carcinoma:

(show top 50) (show all 83)
# Title Authors Year
1
Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma. ( 30776178 )
2019
2
Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report. ( 29409514 )
2018
3
Routine MRI With DWI Sequences to Detect Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Carcinoma and Normal Liver CT: A Prospective Multicenter Study. ( 30240298 )
2018
4
The Clinical Significance of miR-34a in Pancreatic Ductal Carcinoma and Associated Molecular and Cellular Mechanisms. ( 27458977 )
2017
5
Immunohistochemical Antibody Panel for the Differential Diagnosis of Pancreatic Ductal Carcinoma From Gastrointestinal Contamination and Benign Pancreatic Duct Epithelium in Endoscopic Ultrasound-Guided Fine-Needle Aspiration. ( 28099249 )
2017
6
Adjuvant treatment for pancreatic ductal carcinoma. ( 28639051 )
2017
7
Worsened outcome in patients with pancreatic ductal carcinoma on long-term diabetes: association with E-cadherin1 (CDH1) promoter methylation. ( 29273724 )
2017
8
Plasma membrane expression of ZNF185 is a prognostic factor in pancreatic ductal carcinoma. ( 28927124 )
2017
9
Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma. ( 29254283 )
2017
10
Insulin resistance is associated with the aggressiveness of pancreatic ductal carcinoma. ( 27552832 )
2016
11
Efficacy of contrast-enhanced harmonic endoscopic ultrasonography in the diagnosis of pancreatic ductal carcinoma. ( 27184637 )
2016
12
A case report on metastatic pancreatic tumor from pulmonary adenocarcinoma that difficult to differentiate from primary pancreatic ductal carcinoma. ( 27498937 )
2016
13
Second primary pancreatic ductal carcinoma in the remnant pancreas after pancreatectomy for pancreatic ductal carcinoma: High cumulative incidence rates at 5 years after pancreatectomy. ( 27237099 )
2016
14
Alternative splicing of NUMB, APP and VEGFA as the features of pancreatic ductal carcinoma. ( 26261495 )
2015
15
Clinicopathological Significance of ASC-Amino Acid Transporter 2 (ASCT2) Expression in Pancreatic Ductal Carcinoma. ( 24845232 )
2014
16
Alteration of strain ratio evaluated by transabdominal ultrasound elastography may predict the efficacy of preoperative chemoradiation performed for pancreatic ductal carcinoma: preliminary results. ( 24901166 )
2014
17
Successful management of metachronous liver metastasis after pancreaticoduodectomy for pancreatic ductal carcinoma using hepatectomy and chemotherapy: a case report. ( 24778053 )
2014
18
Pancreatic intraglandular metastasis predicts poorer outcome in postoperative patients with pancreatic ductal carcinoma. ( 23648465 )
2013
19
Clinicopathologic assessment of pancreatic ductal carcinoma located at the head of the pancreas, in relation to embryonic development. ( 22228049 )
2012
20
Nm23/nucleoside diphosphate kinase-A as a potent prognostic marker in invasive pancreatic ductal carcinoma identified by proteomic analysis of laser micro-dissected formalin-fixed paraffin-embedded tissue. ( 22892044 )
2012
21
Preoperative platelet-lymphocyte ratio in resected pancreatic ductal carcinoma: is it meaningful? ( 20579970 )
2012
22
Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma. ( 21841817 )
2012
23
Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model. ( 22190076 )
2012
24
Assessment of the interface between retroperitoneal fat infiltration of pancreatic ductal carcinoma and the major artery by multidetector-row computed tomography: surgical outcomes and correlation with histopathological extension. ( 22562451 )
2012
25
KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma. ( 21224073 )
2011
26
Cytologic features of pancreatic intraepithelial neoplasia and pancreatitis: potential pitfalls in the diagnosis of pancreatic ductal carcinoma. ( 20730891 )
2011
27
Expression of KL-6/MUC1 in pancreatic ductal carcinoma and its potential relationship with I^-catenin in tumor progression. ( 21466814 )
2011
28
Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1. ( 21272935 )
2011
29
Asymptomatic curable pancreatic ductal carcinoma detected during the follow-up of pancreatic cysts distinct from carcinoma. ( 26190721 )
2011
30
Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. ( 19856421 )
2010
31
Does contrast-enhanced ultrasound reveal tumor angiogenesis in pancreatic ductal carcinoma? A prospective study. ( 18845377 )
2009
32
Correlations between p53 gene mutations and histologic characteristics of pancreatic ductal carcinoma. ( 19248224 )
2009
33
Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. ( 19020717 )
2008
34
Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma. ( 18505086 )
2008
35
Expression of matrix metalloproteinase 9 in pancreatic ductal carcinoma is associated with tumor metastasis formation. ( 17378244 )
2007
36
Reappraisal of the clinical significance of tumor size in patients with pancreatic ductal carcinoma. ( 17003643 )
2006
37
Pancreatic ductal carcinoma: from the bench to the bedside. ( 16998251 )
2006
38
Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy. ( 17072983 )
2006
39
Contrast-enhanced sonography of pancreatic ductal carcinoma using agent detection imaging. ( 27277616 )
2006
40
Retroviral expression screening of oncogenes in pancreatic ductal carcinoma. ( 16125925 )
2005
41
Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells. ( 16053509 )
2005
42
Evaluation of vascular signal in pancreatic ductal carcinoma using contrast enhanced ultrasonography: effect of systemic chemotherapy. ( 15951559 )
2005
43
Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A. ( 16335935 )
2005
44
Intercalated duct cell is starting point in development of pancreatic ductal carcinoma? ( 16018800 )
2005
45
Factors predicting recurrence after resection of pancreatic ductal carcinoma. ( 15968250 )
2005
46
Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma. ( 15985168 )
2005
47
Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. ( 16136352 )
2005
48
Evaluation of blood flow in pancreatic ductal carcinoma using contrast-enhanced, wide-band Doppler ultrasonography: correlation with tumor characteristics and vascular endothelial growth factor. ( 15084983 )
2004
49
Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives. ( 14745573 )
2004
50
A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. ( 15258755 )
2004

Variations for Pancreatic Ductal Carcinoma

Expression for Pancreatic Ductal Carcinoma

Search GEO for disease gene expression data for Pancreatic Ductal Carcinoma.

Pathways for Pancreatic Ductal Carcinoma

Pathways related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.62 CDKN2A SMAD4 TP53 VEGFA
2 12.58 CDKN2A SMAD4 TP53 VEGFA
3
Show member pathways
12.44 CDKN2A MUC2 SMAD4 TP53
4
Show member pathways
12.01 MUC1 MUC2 MUC6
5 11.94 SMAD4 TP53 VEGFA
6 11.86 SMAD4 TP53 VEGFA
7
Show member pathways
11.8 MUC1 MUC2 MUC6
8 11.67 CDKN2A SMAD4 TP53
9 11.64 MUC1 TP53 VEGFA
10 11.57 CDKN2A SMAD4 TP53
11 11.54 CDKN2A SMAD4 TP53 VEGFA
12 11.23 CDKN2A TP53 VEGFA
13 11.14 SMAD4 TP53 VEGFA
14 11.09 CDKN2A TP53
15 10.99 CDKN2A SMAD4 TP53 VEGFA
16 10.88 CDKN2A TP53
17
Show member pathways
10.87 CDKN2A TP53
18 10.83 MUC2 SMAD4
19 10.79 CDKN2A TP53 TYMP VEGFA

GO Terms for Pancreatic Ductal Carcinoma

Cellular components related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.8 MUC1 MUC2 MUC6

Biological processes related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell growth GO:0030308 9.54 CDKN2A SMAD4 TP53
2 maintenance of gastrointestinal epithelium GO:0030277 9.32 MUC2 MUC6
3 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.26 MUC1 TP53
4 replicative senescence GO:0090399 9.16 CDKN2A TP53
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.13 MUC1 MUC2 MUC6
6 O-glycan processing GO:0016266 8.8 MUC1 MUC2 MUC6

Sources for Pancreatic Ductal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....